Copyright
©The Author(s) 2020.
World J Gastrointest Oncol. Jan 15, 2020; 12(1): 83-91
Published online Jan 15, 2020. doi: 10.4251/wjgo.v12.i1.83
Published online Jan 15, 2020. doi: 10.4251/wjgo.v12.i1.83
Table 1 Patient baseline characteristics
| Characteristic | Value |
| Total, n | 98 |
| Age in yr, median (range) | 60 (22-86) |
| Gender, n (%) | |
| Female | 46 (47) |
| Male | 52 (53) |
| Institution, n (%) | |
| MD Anderson Cancer Center | 61 (62) |
| University of Michigan | 26 (27) |
| Mayo Clinic Cancer Center | 11 (11) |
| Stage at Treatment with FOLFIRI, n (%) | |
| Locally advanced | 24 (25) |
| Metastatic | 74 (75) |
| Subtype of BTC, n (%) | |
| Extrahepatic cholangiocarcinoma | 10 (10) |
| Intrahepatic cholangiocarcinoma | 71 (72) |
| Gallbladder carcinoma | 17 (17) |
| Line of Therapy, n (%) | |
| First | 8 (8) |
| Second | 50 (51) |
| Third | 36 (37) |
| Fourth or greater | 4 (4) |
| Irinotecan-based regimen, n (%) | |
| FOLFIRI | 77 (79) |
| FOLFIRI + bevacizumab | 13 (13) |
| FOLRIRI + anti-EGFR | 5 (5) |
| FOLFIRINOX | 2 (2) |
| FOLFIRI + nab-paclitaxel | 1 (1) |
| ECOG performance status, n (%) | |
| 0 | 11 (11) |
| 1 | 48 (49) |
| 2 | 3 (3) |
| 3 | 2 (2) |
| Not documented | 34 (35) |
- Citation: Mizrahi JD, Gunchick V, Mody K, Xiao L, Surapaneni P, Shroff RT, Sahai V. Multi-institutional retrospective analysis of FOLFIRI in patients with advanced biliary tract cancers. World J Gastrointest Oncol 2020; 12(1): 83-91
- URL: https://www.wjgnet.com/1948-5204/full/v12/i1/83.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v12.i1.83